Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

PURPOSE: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Scher, Howard I., Morris, Michael J., Stadler, Walter M., Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S., Beer, Tomasz M., Carducci, Michael A., Chi, Kim N., Corn, Paul G., de Bono, Johann S., Dreicer, Robert, George, Daniel J., Heath, Elisabeth I., Hussain, Maha, Kelly, Wm. Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N., Rathkopf, Dana E., Slovin, Susan F., Ryan, Charles J., Sartor, Oliver, Small, Eric J., Smith, Matthew Raymond, Sternberg, Cora N., Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S., Schwartz, Lawrence H., Halabi, Susan, Kantoff, Philip W., Armstrong, Andrew J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
Special Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872347/
https://ncbi.nlm.nih.gov/pubmed/26903579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.2702
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados